Watson-Marlow Pumps Group (WMPG) strengthens its single-use biopharmaceutical offering through acquisition of Bio Pure Technology Limited (Bio Pure).
Watson-Marlow, a world-leading positive displacement pump manufacturer, has acquired Bio Pure through its parent company Spirax-Sarco Engineering plc for £8.5 million. Bio Pure, based in Portsmouth UK, specialises in the design and production of advanced single-use tubing connector systems for biopharmaceutical customers.
Bio Pure is a natural extension of the Watson-Marlow peristaltic pump range, complementing its offering in the Biopharmaceutical sector, and joining a portfolio comprising Watson-Marlow Pumps, Watson-Marlow Tubing, Flexicon Filling Systems, Alitea OEM Pumps MasoSine Process Pumps and Bredel Hose Pumps.
WMPG already has a positive commercial relationship with Bio Pure, jointly promoting Watson-Marlow pumps, tubing and Bio Pure connectors to shared customers, where both Bio Pure and Watson-Marlow products are integrated into customers’ equipment. There is clear synergy and a significant growth opportunity presented by bringing together Bio Pure’s product range and WMPG’s products to meet the needs of the rapidly growing single-use biopharmaceutical market. The acquisition strengthens WMPG’s presence in the biotechnology and pharmaceutical industries. In particular, Bio Pure complements WMPG’s existing range of Flexicon peristaltic filling systems and single use tubing, easing customer validation in demanding contamination-free dispensing applications and offering improved sterility for critical applications.
Jay Whalen, President of the Watson-Marlow Pumps Group comments: "The strategic acquisition of Bio Pure further broadens our product range and strengthens Watson-Marlow's position in the single-use biopharmaceutical market. That enables us to provide a more comprehensive and improved service to our customer looking for sterility throughout their fluid path. This is yet another exciting milestone for Watson-Marlow and we are looking forward to accelerating our growth within the biopharmaceutical market with our broadened product portfolio coupled to our process expertise”.
Biopure was established in 1998 by the founder, Roy Maunder, who will continue with the company as a Non-Executive Director. We are pleased that Mr Steven Feasey will continue as Sales Director.